KOL Identification

A top-10 diagnostics player wanted to monitor market development activities and competitive intelligence in the early cancer detection space

A leading diagnostic company wanted an assessment of the future market landscape for low-throughput (LT) molecular diagnostic (MDx) testing to develop a long-term platform strategy to address the future needs of this market

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy

An early-stage venture firm requested a high-level commercial due diligence of a potential investment